Immunogen (IMGN) Tops Q2 EPS by 7c, Offers Guidance
Get Alerts IMGN Hot Sheet
EPS Growth %: +100.0%
Financial Fact:
Total revenues: 7.66M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Immunogen (NASDAQ: IMGN) reported Q2 EPS of ($0.10), $0.07 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $39.02 million versus the consensus estimate of $30.6 million.
Financial Guidance
ImmunoGen has updated its guidance for 2017. Expected revenues are now projected to be between $115 million and $120 million, compared with previous guidance of between $70 million and $75 million; and cash and cash equivalents at December 31, 2017 are expected to be between $90 million and $95 million, compared to previous guidance of $35 million to $40 million. These changes are a result of the Debiopharm and Sanofi agreements executed in the second quarter of 2017. Operating expenses remain unchanged and are expected to be between $175 million and $180 million.
ImmunoGen expects that its current cash plus expected cash revenues from partners and collaborators will enable the Company to fund operations into the second half of 2018.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbus revenue rises, delivers 142 commercial aircraft in Q1
- PHINIA Inc. (PHIN) Reports Q1 EPS of $1.08, provides guidance
- Integer Holdings Corp (ITGR) Tops Q1 EPS by 2c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!